Rifabutin: Difference between revisions
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
'''Rifabutin''' ('''Rfb''') is a [[bactericidal]] [[antibiotic]] drug primarily used in the treatment of [[tuberculosis]]. The drug is a semi-synthetic derivative of [[rifamycin]] S. Its effect is based on blocking the DNA-dependent RNA-polymerase of the bacteria. It is effective against [[Gram-positive]] and some [[Gram-negative]] bacteria, but also against the highly resistant [[Mycobacteria]], e.g. ''[[Mycobacterium tuberculosis]]'', ''[[Mycobacterium leprae|M. leprae]]'', and ''[[Mycobacterium avium intracellulare|M. avium intracellulare]]''. | |||
==Category== | ==Category== | ||
Revision as of 02:16, 31 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Rifabutin (Rfb) is a bactericidal antibiotic drug primarily used in the treatment of tuberculosis. The drug is a semi-synthetic derivative of rifamycin S. Its effect is based on blocking the DNA-dependent RNA-polymerase of the bacteria. It is effective against Gram-positive and some Gram-negative bacteria, but also against the highly resistant Mycobacteria, e.g. Mycobacterium tuberculosis, M. leprae, and M. avium intracellulare.
Category
US Brand Names
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages